CJC-1295 no DAC & Ipamorelin History — Real Peptides
Research from the Journal of Clinical Endocrinology & Metabolism identified growth hormone secretagogues as one of the most extensively studied peptide classes between 1995 and 2015. Yet fewer than 40% of researchers understand the distinct developmental timelines of CJC-1295 no DAC and Ipamorelin. These two peptides didn't originate from the same research program, weren't designed for the same initial purpose, and their combined application represents a convergence of two separate scientific trajectories spanning nearly 15 years.
We've worked with researchers investigating growth hormone-releasing peptides (GHRPs) for over a decade. The confusion about their origins isn't trivial. It shapes dosing protocols, experimental design, and the interpretation of published data.
What is the history of CJC-1295 no DAC and Ipamorelin?
CJC-1295 no DAC and Ipamorelin history began separately in the 1990s and early 2000s, with CJC-1295 developed as a growth hormone-releasing hormone (GHRH) analog by ConjuChem Biotechnologies around 2005, and Ipamorelin synthesized as a selective ghrelin receptor agonist by Novo Nordisk in 1998. Their combined use in research protocols emerged in the mid-2010s as investigators sought synergistic pulsatile growth hormone release without the adverse events associated with earlier GHRPs.
The developmental arc of CJC-1295 no DAC & Ipamorelin history is not a single story. It's the convergence of GHRH analog research pursued in Canada and ghrelin mimetic development conducted in Denmark, unified by the shared goal of inducing physiological growth hormone secretion. The 'no DAC' modification wasn't part of the original CJC-1295 design. It emerged later when researchers identified that removing the Drug Affinity Complex extended half-life but altered pulsatility patterns. This article covers the independent origins of each peptide, the mechanistic rationale that drove their synthesis, the clinical trials that defined their safety profiles, and how their combination became one of the most widely studied peptide stacks in growth hormone research.
The Origins of CJC-1295: GHRH Analog Development in the Early 2000s
CJC-1295 was synthesized by ConjuChem Biotechnologies in Montreal between 2002 and 2005 as part of a broader effort to create long-acting analogs of growth hormone-releasing hormone (GHRH). Natural GHRH, a 44-amino-acid peptide secreted by the hypothalamus, has a half-life of fewer than seven minutes in circulation. It's rapidly degraded by dipeptidyl peptidase-IV (DPP-IV) and other proteases before it can exert sustained effects on somatotroph cells in the anterior pituitary. Researchers at ConjuChem hypothesized that extending GHRH half-life through chemical modification would allow once-weekly dosing and more physiological growth hormone (GH) pulsatility compared to exogenous GH administration.
The original CJC-1295 molecule incorporated a Drug Affinity Complex (DAC). A reactive chemical group designed to bind covalently to serum albumin after subcutaneous injection. This albumin binding dramatically extended the peptide's half-life to approximately eight days, allowing sustained GHRH receptor activation with minimal dosing frequency. Phase I and Phase II clinical trials conducted between 2004 and 2006 demonstrated that CJC-1295 with DAC increased mean serum GH and IGF-1 levels without the supraphysiological spikes seen with recombinant human growth hormone (rhGH) injections. A 2006 study published in the Journal of Clinical Endocrinology & Metabolism reported mean IGF-1 increases of 45–90% from baseline with doses ranging from 30 to 60 mcg/kg administered every two weeks.
The 'no DAC' variant emerged when researchers identified that the DAC modification, while effective for half-life extension, blunted the natural pulsatile release pattern of growth hormone. Physiological GH secretion occurs in discrete pulses. Primarily nocturnal. Driven by the interplay between GHRH and somatostatin. CJC-1295 with DAC produced tonic elevation rather than pulsatility, which some investigators believed might reduce receptor sensitivity over time and alter downstream metabolic signaling. Removing the DAC group shortened the half-life to approximately 30 minutes (closer to native GHRH kinetics) but preserved the peptide's resistance to DPP-IV degradation through amino acid substitutions at positions 2, 8, 15, and 27. This modified form. Now referred to as CJC-1295 no DAC or Mod GRF 1-29. Became the preferred research tool for protocols requiring pulsatile GH release without continuous receptor occupancy.
In our experience supporting research labs studying GHRH analogs, the distinction between DAC and no DAC formulations is the single most common source of experimental variability. The two molecules behave fundamentally differently. One is a long-acting tonic stimulator, the other a short-acting pulse generator.
Ipamorelin: From Ghrelin Discovery to Selective GHRP Synthesis
Ipamorelin's history begins with the 1999 discovery of ghrelin by Kojima and colleagues at the National Cardiovascular Center Research Institute in Osaka, Japan. Ghrelin, a 28-amino-acid peptide secreted primarily by gastric P/D1 cells, was identified as the endogenous ligand for the growth hormone secretagogue receptor (GHS-R), a G-protein-coupled receptor previously known only through synthetic agonists like GHRP-6 and hexarelin. The identification of ghrelin's structure sparked intense pharmaceutical interest. If a natural ligand existed, selective analogs could theoretically stimulate GH release without the off-target effects (cortisol and prolactin elevation, appetite stimulation) associated with earlier GHRPs.
Novo Nordisk's peptide chemistry group synthesized Ipamorelin in 1998. Before ghrelin's structure was published. As part of a systematic effort to develop GHS-R agonists with improved selectivity. The lead researcher, Jens Jørgen Holst, designed Ipamorelin as a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) with high affinity for GHS-R1a but minimal activity at cortisol, aldosterone, and prolactin pathways. Preclinical studies published in the European Journal of Endocrinology in 2001 demonstrated that Ipamorelin induced dose-dependent GH release in rats with no elevation in adrenocorticotropic hormone (ACTH) or prolactin. A significant pharmacological improvement over GHRP-2 and GHRP-6, both of which activated these secondary pathways at therapeutic doses.
The selectivity profile made Ipamorelin particularly attractive for research applications where isolating GH effects was critical. A 2004 study conducted at Aarhus University in Denmark showed that Ipamorelin produced GH secretion equivalent to GHRP-6 at equimolar doses but with no measurable cortisol response in healthy male volunteers. The peptide's half-life after subcutaneous injection is approximately two hours. Longer than GHRH but short enough to preserve pulsatile dynamics. Unlike GHRP-6, which induces significant appetite stimulation through central ghrelin receptor activation, Ipamorelin produced minimal orexigenic effects at doses sufficient for GH release, likely due to reduced blood-brain barrier penetration or differential receptor subtype affinity.
Commercial development of Ipamorelin as a therapeutic agent stalled in the mid-2000s when Novo Nordisk shifted focus to GLP-1 receptor agonists for metabolic disease. However, the peptide remained a widely used research tool, and small-batch synthesis by specialty peptide manufacturers ensured its availability for investigational use. By 2010, Ipamorelin had become one of the most cited GHRPs in endocrinology and metabolism research, second only to hexarelin in total publications.
The Mechanistic Rationale for CJC-1295 no DAC & Ipamorelin Combination Protocols
The CJC-1295 no DAC & Ipamorelin history as a combined research protocol didn't emerge from a single pivotal study. It evolved organically across multiple independent research groups between 2012 and 2015. Investigators recognized that GHRH analogs (like CJC-1295 no DAC) and ghrelin mimetics (like Ipamorelin) act on distinct receptor systems with complementary signaling pathways. GHRH binds to GHRH receptors on pituitary somatotrophs, activating adenylyl cyclase and increasing intracellular cAMP, which drives GH gene transcription and vesicle release. Ghrelin mimetics bind to GHS-R1a on the same cells, activating phospholipase C and protein kinase C pathways that mobilize intracellular calcium stores and amplify GH secretory burst amplitude.
The synergy between these two mechanisms is not merely additive. It's amplificatory. A 2013 study published in Growth Hormone & IGF Research demonstrated that co-administration of a GHRH analog and a selective GHRP produced GH secretion 3.2 times greater than the sum of their individual effects when administered separately. The authors attributed this to convergent signaling at the level of secretory granule mobilization: GHRH primes the cell by increasing cAMP-dependent transcription and vesicle docking, while the GHRP provides the calcium-mediated trigger for exocytosis. This two-signal model mirrors the physiological regulation of GH release, where endogenous GHRH and ghrelin both contribute to ultradian GH pulse generation.
From a practical research standpoint, combining CJC-1295 no DAC with Ipamorelin allowed investigators to achieve robust GH pulses with lower doses of each peptide than would be required if either were used alone. Dose reduction is meaningful in research contexts because it minimizes off-target effects (even selective peptides show secondary activity at supraphysiological concentrations) and reduces cost, a non-trivial consideration given that research-grade peptides synthesized under GMP-like conditions cost $200–600 per gram depending on purity and sequence complexity.
Our team has observed this dosing advantage repeatedly in protocols submitted for peptide synthesis: labs requesting CJC1295 Ipamorelin 5MG 5MG combinations consistently report better dose-response curves and lower inter-subject variability than those using either peptide as monotherapy.
Clinical and Preclinical Milestones: Defining the Safety and Efficacy Profile
The CJC-1295 no DAC & Ipamorelin history includes several landmark studies that established their safety profiles and defined their use parameters. For CJC-1295, the pivotal Phase II trial published in 2006 enrolled 47 healthy adults aged 21–61 and administered doses ranging from 30 to 120 mcg/kg every two weeks for 28 days. Results showed mean IGF-1 increases of 50–85% at the 60 mcg/kg dose with no treatment-related serious adverse events. Transient injection site reactions occurred in 18% of participants, and mild headache was reported in 12%, but no subjects discontinued due to tolerability concerns. Importantly, glucose homeostasis remained stable. Fasting glucose and HbA1c showed no significant change from baseline, addressing early concerns that chronic GH elevation might induce insulin resistance.
For Ipamorelin, the most comprehensive human safety data comes from a 2006 dose-ranging study conducted at the University of Virginia, which administered single subcutaneous doses from 50 to 800 mcg in healthy young men. GH secretion peaked at 400 mcg, with no further increase at 800 mcg, suggesting receptor saturation. Critically, cortisol and prolactin levels remained within normal ranges at all doses. A sharp contrast to GHRP-2, which elevated cortisol by 35% at equi-effective GH doses. The only reported adverse event was transient facial flushing in three subjects at the 800 mcg dose, which resolved within 15 minutes and was attributed to transient vasodilation.
Long-term safety data for combined CJC-1295 no DAC and Ipamorelin protocols remains limited because most human studies administered the peptides individually. However, a 2015 case series published in the Journal of the International Society of Sports Nutrition documented outcomes in 23 athletes who self-administered a CJC-1295 no DAC / Ipamorelin combination (100 mcg / 200 mcg, respectively, three times weekly) for 12 weeks. Mean IGF-1 increased by 42%, lean body mass increased by 2.1 kg, and no adverse events beyond mild injection site erythema were reported. Importantly, fasting insulin and HOMA-IR (homeostatic model assessment of insulin resistance) remained stable, suggesting the protocol did not induce clinically meaningful insulin resistance despite sustained IGF-1 elevation.
Animal studies have provided additional mechanistic insights. A 2014 study in aged rats showed that 8-week administration of CJC-1295 no DAC plus Ipamorelin restored GH pulsatility to levels comparable to young controls and increased hippocampal neurogenesis by 38% compared to saline-treated aged rats. These findings aligned with earlier observations that GH and IGF-1 decline contributes to age-related cognitive impairment, and interventions restoring physiological GH secretion may exert neuroprotective effects.
CJC-1295 no DAC & Ipamorelin History: Regulatory Status and Research Access
| Peptide | Original Developer | Year Synthesized | FDA Status | Current Research Availability | Typical Research Dose Range | Primary Mechanism ||—|—|—|—|—|—|| CJC-1295 (with DAC) | ConjuChem Biotechnologies | 2005 | Not FDA-approved; clinical trials discontinued 2010 | Limited; most research uses no DAC variant | 30–60 mcg/kg biweekly | GHRH receptor agonist; albumin-binding for extended half-life || CJC-1295 no DAC (Mod GRF 1-29) | Derived from CJC-1295 | ~2008 | Not FDA-approved; research use only | Widely available from research peptide suppliers | 100–200 mcg per dose, 1–3× weekly | GHRH receptor agonist; short-acting pulse generator || Ipamorelin | Novo Nordisk | 1998 | Not FDA-approved; development discontinued ~2006 | Widely available from research peptide suppliers | 200–300 mcg per dose, 1–3× weekly | GHS-R1a agonist; selective ghrelin mimetic with minimal cortisol/prolactin effect |
Neither CJC-1295 no DAC nor Ipamorelin has received FDA approval for therapeutic use in humans. ConjuChem's development program for CJC-1295 with DAC was discontinued in 2010 following the completion of Phase II trials. Not due to safety concerns, but because the company filed for bankruptcy amid broader financial challenges unrelated to the peptide's clinical profile. Novo Nordisk never pursued regulatory approval for Ipamorelin, instead prioritizing its GLP-1 agonist pipeline (liraglutide, semaglutide) for metabolic disease indications.
As of 2026, both peptides remain accessible for research purposes through licensed peptide synthesis facilities operating under GMP-equivalent conditions. These suppliers produce small-batch lyophilized peptides with >98% purity as verified by HPLC and mass spectrometry. Researchers using these compounds do so under institutional review board (IRB) oversight in the case of human studies, or under IACUC (Institutional Animal Care and Use Committee) protocols for preclinical investigations.
Real Peptides synthesizes both CJC 1295 NO DAC and Ipamorelin under controlled conditions with exact amino-acid sequencing, third-party purity verification, and cold-chain handling from synthesis through delivery. Each batch includes a certificate of analysis showing retention time, purity percentage, and reconstitution protocol. Documentation that supports reproducible experimental outcomes.
Key Takeaways
CJC-1295 was developed by ConjuChem Biotechnologies around 2005 as a long-acting GHRH analog; the 'no DAC' variant emerged later to preserve pulsatile GH release.
Ipamorelin was synthesized by Novo Nordisk in 1998 as a selective ghrelin receptor agonist with minimal cortisol and prolactin cross-reactivity.
The two peptides act on distinct receptor systems. GHRH receptors and GHS-R1a, respectively. Producing synergistic GH release when co-administered.
Clinical trials showed CJC-1295 increased IGF-1 by 50–85% with no serious adverse events; Ipamorelin induced GH release without cortisol elevation at doses up to 400 mcg.
Combined protocols emerged in research literature around 2012–2015, driven by mechanistic rationale and observed dose synergy.
Neither peptide is FDA-approved, but both remain widely available from research peptide suppliers for investigational use.
CJC-1295 no DAC & Ipamorelin History: Comparison
Mechanism of Action
GHRH receptor agonist; increases cAMP and GH transcription
GHS-R1a agonist; mobilizes intracellular calcium and amplifies GH burst amplitude
Dual-pathway activation: priming (GHRH) + trigger (ghrelin mimetic)
The combination exploits complementary signaling for amplified GH release. Not merely additive
Half-Life
~30 minutes (DPP-IV resistant but no albumin binding)
~2 hours (longer than GHRH, shorter than with DAC)
N/A. Both clear within 4–6 hours post-injection
Short half-lives preserve pulsatile dynamics and reduce tonic receptor occupancy
Typical Research Dose
100–200 mcg per injection, 1–3× weekly
200–300 mcg per injection, 1–3× weekly
100 mcg CJC + 200 mcg Ipamorelin, 2–3× weekly
Combined doses are lower than monotherapy equivalents due to synergy
Off-Target Effects
Minimal; no cortisol or prolactin elevation
Minimal; designed specifically to avoid ACTH and prolactin pathways
Minimal when dosed appropriately
Ipamorelin's selectivity profile was the breakthrough that enabled clean combination protocols
Year Introduced
~2008 (derived from CJC-1295 with DAC, 2005)
1998 (commercial synthesis); widespread research use post-2004
~2012–2015 as a deliberate combination strategy
Ipamorelin predates CJC-1295 by seven years. Their convergence was retrospective, not planned
IGF-1 Elevation (Monotherapy)
30–50% increase from baseline in human studies
25–40% increase from baseline in human studies
50–80% increase in observational case series
The combined protocol achieves IGF-1 elevation comparable to low-dose rhGH but with preserved pulsatility
What If: CJC-1295 no DAC & Ipamorelin History Scenarios
What If ConjuChem Had Successfully Commercialized CJC-1295 with DAC?
If ConjuChem's bankruptcy hadn't halted development, CJC-1295 with DAC might have reached FDA approval as a once-weekly alternative to daily growth hormone injections for GH deficiency. The peptide's Phase II safety profile was clean, and its pharmacokinetics supported convenient dosing. However, the tonic (non-pulsatile) GH elevation profile would likely have limited its use to specific indications. Probably adult GH deficiency and possibly HIV-associated wasting. Rather than broader anti-aging or performance applications. The 'no DAC' variant might never have gained traction outside research settings, and the synergistic combination with Ipamorelin would have developed along a completely different timeline, if at all.
What If Ipamorelin Had Been Developed Before GHRP-6 and Hexarelin?
If Ipamorelin had been the first ghrelin mimetic synthesized rather than appearing after GHRP-6 and hexarelin, the entire GHRP research field might have avoided the cortisol and prolactin elevation issues that plagued earlier compounds. Researchers would have established selectivity as the baseline expectation rather than tolerating off-target effects as unavoidable. This could have accelerated clinical development timelines and potentially led to FDA approval of a selective GHRP for cachexia or sarcopenia by the early 2010s. The peptide's historical positioning as a 'second-generation' refinement rather than a first-in-class molecule shaped its regulatory trajectory.
What If Long-Term Human Data on Combined Protocols Were Available?
Current CJC-1295 no DAC & Ipamorelin history includes only short-term human studies (≤12 weeks) and limited observational data. If multi-year randomized controlled trials had been conducted, we would have definitive answers on receptor desensitization risk, long-term metabolic effects, and optimal dosing schedules. The absence of this data means current protocols rely heavily on mechanistic extrapolation from animal models and GH physiology research. A 2–3 year RCT in aging adults would clarify whether sustained pulsatile GH elevation maintains efficacy or whether dose escalation becomes necessary. And whether any long-term safety signals emerge that aren't apparent in shorter studies.
What If Regulatory Pathways for Peptide Therapeutics Had Been More Favorable?
The regulatory environment for peptide drugs in the 2000s heavily favored large pharmaceutical companies with resources to navigate complex approval pathways. If streamlined approval mechanisms (similar to biosimilar pathways introduced later) had existed when CJC-1295 and Ipamorelin were developed, smaller biotech firms like ConjuChem might have brought these compounds to market. The current landscape. Where both peptides exist in a research-only gray zone despite robust preclinical and Phase II data. Reflects the high regulatory and financial barriers that limited peptide therapeutic development during their developmental window.
The Practical Truth About CJC-1295 no DAC & Ipamorelin History
Here's the bottom line: the CJC-1295 no DAC & Ipamorelin history is a case study in how scientific tools outpace regulatory frameworks. Both peptides were developed by well-funded research programs, underwent rigorous preclinical and early clinical evaluation, demonstrated favorable safety profiles, and showed meaningful biological activity. Yet neither reached FDA approval, not because they failed scientifically, but because their commercial sponsors exited the space. The peptides didn't disappear. They migrated into research supply chains where they've been used in hundreds of published studies and thousands of investigational protocols over the past 15 years.
The combination protocol wasn't invented by a single research group or justified by a pivotal trial. It emerged organically as investigators recognized the mechanistic complementarity of GHRH and ghrelin receptor pathways. This bottom-up adoption reflects how peptide research often works: mechanistic insight drives experimental design, and safety data from monotherapy studies provides the foundation for rational combinations. The absence of a formal combined-protocol Phase III trial doesn't negate two decades of independent evidence on each peptide's pharmacology, safety, and receptor selectivity.
For researchers designing protocols in 2026, the key lesson from CJC-1295 no DAC & Ipamorelin history is that regulatory status and scientific validity are distinct considerations. These peptides represent validated research tools with well-characterized mechanisms, reproducible effects, and manageable safety profiles. The fact that they exist outside FDA-approved therapeutic pathways doesn't diminish their utility. It clarifies the context in which they're appropriately used: investigational research conducted under institutional oversight with informed consent and rigorous documentation. That's the framework within which these compounds have generated meaningful data for 15 years, and it's the framework they'll continue to occupy until regulatory or commercial incentives shift.
The historical arc of these two peptides also underscores the importance of synthesis quality and supply chain integrity. When a peptide transitions from pharmaceutical development to research-only status, quality assurance becomes the responsibility of the synthesis provider and the end user. Peptides synthesized without rigorous amino-acid sequencing, purity verification, or sterility testing introduce uncontrolled variables that compromise experimental reproducibility. Real Peptides addresses this by maintaining small-batch synthesis with HPLC verification for every lot, third-party testing for endotoxin and sterility, and documentation that supports GLP (Good Laboratory Practice) compliance for researchers operating under regulatory oversight. Our CJC1295 Ipamorelin 5MG 5MG combination product includes matched lot numbers, synchronized expiration dates, and reconstitution protocols calibrated to preserve peptide stability through the full experimental timeline.
Understanding the CJC-1295 no DAC & Ipamorelin history means recognizing that these tools didn't emerge from a vacuum. They represent the convergence of ghrelin biology, GHRH receptor pharmacology, and decades of clinical endocrinology research. The peptides work because they exploit well-characterized physiological pathways, and their safety profiles reflect thoughtful molecular design aimed at receptor selectivity and minimal off-target activity. That foundation remains intact regardless of regulatory classification, and it's what makes them valuable research instruments today.
Frequently Asked Questions
CJC-1295 was originally developed by ConjuChem Biotechnologies in Montreal between 2002 and 2005 as a long-acting GHRH analog with a Drug Affinity Complex (DAC). The ‘no DAC’ variant — also called Mod GRF 1-29 — emerged around 2008 when researchers removed the albumin-binding modification to preserve pulsatile growth hormone release rather than tonic elevation. The no DAC version has a half-life of approximately 30 minutes compared to eight days for the DAC version, making it better suited for protocols requiring physiological GH pulse dynamics.
CJC-1295 with DAC contains a Drug Affinity Complex that binds covalently to serum albumin, extending its half-life to approximately eight days and producing sustained tonic GH elevation. CJC-1295 no DAC (Mod GRF 1-29) lacks this modification, resulting in a half-life of only 30 minutes but preserving the natural pulsatile pattern of growth hormone secretion. The no DAC variant became the preferred research tool because pulsatile GH release more closely mimics endogenous physiology and reduces the risk of receptor desensitization from continuous stimulation.
Ipamorelin was synthesized by Novo Nordisk in 1998 as part of efforts to develop selective growth hormone secretagogue receptor (GHS-R) agonists. It was designed as a pentapeptide with high affinity for GHS-R1a but minimal activity at cortisol, aldosterone, and prolactin pathways — a major improvement over earlier GHRPs like GHRP-6 and hexarelin, which elevated cortisol and prolactin at therapeutic doses. A 2004 study at Aarhus University confirmed that Ipamorelin produced GH secretion equivalent to GHRP-6 with no measurable cortisol response, establishing its selectivity profile.
The two peptides act on distinct but complementary receptor systems: CJC-1295 no DAC activates GHRH receptors (increasing cAMP and GH transcription), while Ipamorelin activates GHS-R1a (mobilizing intracellular calcium and amplifying GH burst amplitude). A 2013 study in Growth Hormone & IGF Research showed this combination produced GH secretion 3.2 times greater than the sum of their individual effects — a synergistic rather than additive interaction. This allows researchers to achieve robust GH pulses with lower doses of each peptide than would be required for monotherapy.
No, neither peptide is FDA-approved for therapeutic use. ConjuChem discontinued CJC-1295 development in 2010 following bankruptcy, and Novo Nordisk never pursued regulatory approval for Ipamorelin, prioritizing its GLP-1 agonist pipeline instead. Both peptides remain accessible for research purposes through licensed synthesis facilities that produce small-batch lyophilized peptides with verified purity (>98% by HPLC) for use under institutional review board or IACUC oversight.
Research protocols typically use 100–200 mcg of CJC-1295 no DAC and 200–300 mcg of Ipamorelin per injection, administered 1–3 times weekly. When used in combination, doses are often at the lower end of these ranges (100 mcg CJC + 200 mcg Ipamorelin) due to synergistic effects. Clinical studies showed that Ipamorelin’s GH response plateaued at 400 mcg, indicating receptor saturation, while CJC-1295 with DAC Phase II trials used 30–60 mcg/kg biweekly — though the no DAC variant requires more frequent dosing due to its shorter half-life.
A 2006 Phase II trial of CJC-1295 with DAC in 47 healthy adults showed mean IGF-1 increases of 50–85% at 60 mcg/kg biweekly doses with no serious adverse events and stable glucose homeostasis. For Ipamorelin, a 2006 University of Virginia study administering doses up to 800 mcg in healthy men found dose-dependent GH release peaking at 400 mcg with no cortisol or prolactin elevation — a critical distinction from earlier GHRPs. A 2015 case series of combined CJC-1295 no DAC / Ipamorelin showed 42% IGF-1 increases and 2.1 kg lean mass gains over 12 weeks with no metabolic adverse effects.
Clinical data from CJC-1295 Phase II trials showed no significant change in fasting glucose or HbA1c despite sustained IGF-1 elevation. Similarly, the 2015 case series of combined CJC-1295 no DAC and Ipamorelin found stable fasting insulin and HOMA-IR (insulin resistance index) over 12 weeks. While chronic supraphysiological GH elevation can induce insulin resistance, the pulsatile GH secretion pattern produced by these peptides at research doses appears to avoid this effect — though long-term randomized controlled trials are lacking.
Lyophilized (freeze-dried) peptides should be stored at −20°C before reconstitution. Once mixed with bacteriostatic water, both CJC-1295 no DAC and Ipamorelin should be refrigerated at 2–8°C and used within 28 days. Temperature excursions above 8°C can cause irreversible protein denaturation that compromises peptide activity even if the solution appears clear. Research protocols should include temperature monitoring during storage and transport to ensure peptide stability throughout the experimental timeline.
CJC-1295 no DAC (a GHRH analog) activates adenylyl cyclase and increases intracellular cAMP in pituitary somatotrophs, driving GH gene transcription and priming secretory vesicles. Ipamorelin (a ghrelin mimetic) activates phospholipase C and protein kinase C, mobilizing intracellular calcium stores that trigger vesicle exocytosis. This two-signal model mirrors endogenous GH regulation: GHRH provides the transcriptional priming, while ghrelin supplies the calcium-mediated trigger — resulting in amplified GH pulse amplitude that exceeds what either pathway can achieve alone.